TB Alliance: Putting science to work for a faster TB cure

Follow Us:

Open Forum 3

This two-day Open Forum was the third in a series of meetings aimed to raise and address key issues in TB drug development, with a special focus on regulatory affairs.

The Forum included sessions on the current global TB drug development portfolio, key issues in the critical path to TB drug registration, designing pivotal trials, conducting registration trials in high burden countries, challenges in TB drug development for resistant disease and developing regimens containing multiple novel agents.

These meetings are designed to bring together regulators, TB drug developers and other interested stakeholders, such as TB care providers, public health policy-makers, and community advocates from both major industrialized and high burden countries.

Click here to download the Final Meeting Agenda [.pdf - 134k]

This meeting was supported in part by unrestricted educational grants from AstraZeneca, Bayer, GlaxoSmithKline, Johnson & Johnson/Tibotec and sanofi-aventis.

view a webcast of the Open Forum 3 courtesy of Kaiser Family Foundation

Day One: 5 May 2008

Day Two: 6 May 2008